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We present a succinct review of our approach to study the interactions between the DNA-reactive
antibodies that cross-react with the GluN2A and GluN2B subunits of the N-methyl-D-aspartate
receptor, denoted DNRABs, and their brain targets in subjects with neuropsychiatric systemic
lupus erythematosus (NPSLE). We have analyzed the DNRAB-based brain symptomatology in
mouse models of NPSLE by using an integrative neuroscience approach, which includes
behavioral assessment coupled with electrophysiological studies of neural networks and synaptic
connections in target brain regions, such as the CA1 region of the hippocampus. Our results
suggest a framework for understanding the interactions between immune factors and neural
networks.

NMDAR; Mouse; Hippocampus; Cognition; Brain autoimmunity

NPSLE and cognitive impairment
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Systemic lupus erythematosus (SLE) is a chronic immune disorder that affects many organs
in the body. At least 5 million individuals suffer SLE worldwide, with up to 90 % of them
being women of childbearing age. In the USA, it occurs at higher frequency in populations
of African American, Hispanic, and Asian American origin [1]. Neuropsychiatric systemic
lupus erythematosus (NPSLE) refers to the collection of syndromes, ranging from psychosis
to memory problems, which target the nervous system in 40–90 % of subjects with SLE [2–
9]. Many NPSLE manifestations occur at the onset or within the first year of SLE diagnosis,
and are uncorrelated with active systemic disease and serologic activity [10]. NPSLE is
accompanied by a variable burden of disability and significantly diminishes quality of life.
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NPSLE can be identified with the use of 19 criteria established by an expert committee of
the American College of Rheumatology (ACR); twelve of which affect the central nervous
system (CNS) and seven the peripheral nervous system [3]. CNS involvement can be diffuse
(as in the cases of cognitive dysfunction, mood disorder, anxiety disorder, and psychosis),
focal (as in cerebrovascular disease), or complex (mixture of diffuse and focal). However,
the bewildering array of reversible and irreversible symptoms attributable to brain
dysfunction and caused by NPSLE has hampered a mechanistic understanding. It is
therefore critical to explore innovative paradigms to understand the pathophysiological
mechanisms of this vexing problem in SLE.
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Cognitive impairment (CI) is highly prevalent in NPSLE, ranging from 20 to 80 % [4–7, 11–
17]. Loss of cognitive function, as defined by the ACR, is characterized by impairment in
one or more of the following cognitive domains: simple attention, complex attention,
memory, visual-spatial processing, language, reasoning, problem solving, psychomotor
speed, and executive functions. Most studies suggest a slow cognitive decline and no
association with disease activity [18–21]. It is somewhat perplexing that the wide-ranging
prevalence of CI reflects the methodological variations by which it has been measured rather
than biological differences [17, 22–24]. The course of CI has been described as evanescent
and fluctuating over a 2- to 5-year period [25, 26] but progressing slowly over longer
periods, and even reaching the severity of dementia in 3–5 % of subjects with SLE [25–29].
Unambiguous CI signs can be challenging to ascertain clinically [29], but strict adherence to
the ACR standard (which proposes a 1-h battery of neuropsychological tests) together with
the emergence of improved cognitive tests might yield more exact CI estimates in NPSLE
patients.
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Brain-reactive antibodies in NPSLE
The pathogenesis of NPSLE has been linked with several immune factors, such as
inflammatory cytokines, autoantibodies, and immune complexes. For instance,
cerebrovascular disease in NPSLE, a focal type of insult, may result from vascular insults
(such as thrombosis) mediated by anti-phospholipid antibodies, accelerated atherosclerosis,
and the non-deformability of red blood cells that are coated with immune complexes [30–
32].
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Early studies have demonstrated that serum antibodies from subjects with SLE bind to
normal brain tissue [33–38]. The occurrence of antibodies capable of altering the function of
neuronal cells offers a promising avenue to study the diffuse CNS syndromes associated
with NPSLE. Indeed, an increasing number of studies have strengthened the idea that some
non-focal symptoms can be linked to the presence of DNRABs, a subclass of DNA-reactive
antibodies that bind the GluN2A and GluN2B subunits of the n-methyl-d-as-partate receptor
(NMDAR) with very high specificity and do not appear to bind any other brain molecule
[39–49]. There is now compelling evidence for the pathogenic role of DNRABs in NPSLE
[50–55] suggesting that these antibodies can cause more than one manifestation, specifically
memory dysfunction and emotional disturbance, depending on the mechanisms by which
DNRABs penetrate the blood–brain barrier (BBB) that separates the brain from circulation.
Several investigators have started using these paradigms to test brain effects of other SLE-

Immunol Res. Author manuscript; available in PMC 2016 June 23.

Huerta et al.

Page 3

Author Manuscript

related autoantibodies [56–59]. Interestingly, these antibody molecules are likely to be
polyreactive, that is, capable of binding a variety of structurally unrelated brain antigens.

NMDAR: synaptic receptor targeted by NPSLE
We have developed a strategy to study the effects of DNRABs in the brain based on the
seminal finding that these autoantibodies recognize a linear 5-amino acid sequence
consisting of D/E, W, D/E, Y, and S/G [39]. This epitope is localized in the extracellular,
amino-terminal domains of GluN2A (residues 283–287, sequence DWDYS) and GluN2B
(residues 284–288, sequence EWDYG); each subunit is an essential component of the
NMDAR [60].

Author Manuscript

NMDARs are localized within the most abundant synapses of the forebrain, which use
glutamate as the neurotransmitter, and connect excitatory neurons in brain regions such as
the cerebral cortex, the hippocampus, and the amygdala [61–63]. During excitatory synaptic
transmission, glutamate is released from presynaptic terminals and binds to ligand-gated
receptors on the postsynaptic membrane, the most common of which are the NMDARs [61–
63] and the amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors (AMPARs)
[64]. The latter mediate fast excitation, through the influx of sodium into the postsynaptic
cell, which results in rapid depolarization of the postsynaptic membrane. NMDARs mediate
a slower and longer-lasting excitation through the influx of calcium. Normally, NMDARs
participate in synaptic plasticity largely because of their high calcium permeability and slow
deactivation and desensitization kinetics [61–63, 65–68]. These very same properties,
however, allow NMDARs to trigger excitotoxicity and apoptosis under abnormal conditions
[69–71].
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In the forebrain, functional NMDARs are assembled as a pair of GluN1 subunits and a pair
of GluN2 subunits. GluN1s are essential channel-forming subunits, and they bind glycine
and determine calcium permeability [65], while GluN2 subunits bind glutamate and contain
regions that regulate deactivation and desensitization [65]. NMDARs are also voltagedependent, becoming activated only during significant postsynaptic depolarization. In the
resting state, the pore of the ion channel formed by the NMDAR is blocked by magnesium,
which during the depolarized state is forced out of the pore, allowing calcium to enter into
the postsynaptic cell [68]. NMDARs can be thought as associative gates, requiring
presynaptic activity (glutamate) and postsynaptic activity (depolarization) to be activated
[68]. Moreover, electrophysiological studies have determined that the response of GluN1–
GluN2A complexes is short (~100 ms) when compared to GluN1–GluN2B complexes (~250
ms), implying that the latter lead to higher calcium influx into the postsynaptic cell [72].
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NMDARs in the hippocampus are essential for the acquisition of certain types of memory.
The hippocampus is organized into interconnected regions: the dentate gyrus (DG), the
cornu ammonis (CA) areas (CA1, CA2, and CA3), and the subiculum [73, 74]. These areas
receive projections from, and project back to, the cerebral cortex. Much research has focused
on the hippocampus to provide insight into the neural substrates of memory. It is well
documented that humans with damage to this brain region exhibit episodic memory
impairment, but can otherwise function normally [74–76]. Similarly, rodents with
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hippocampal lesions are severely impaired in tasks that depend on memories in the spatial
and temporal domains [78–82]. With the use of genetic techniques, we have demonstrated
that mice in which the NMDARs have been deleted from the CA1 pyramidal cells are unable
to establish spatial and temporal memories [81, 82], confirming the lesion studies and
providing more detailed information on the molecular requirements for hippocampal
memory function.

Integrative neuroscience applied to NPSLE

Author Manuscript

We have analyzed the effects of DNRABs at different levels of neural organization, from
molecules and synapses to brain regions and whole-brain (Fig. 1), and have identified
alterations that, in combination, provide a multilevel mechanism for the deleterious action of
DNRABs within the brain. The pioneering work by Betty Diamond and collaborators [39]
identified cross-reactive antigens for anti-double-stranded deoxyribonucleic acid (antidsDNA) antibodies; they found a nephritogenic mouse monoclonal anti-dsDNA antibody,
termed R4A, which was reacted with a phage peptide display library harboring random 10
amino acid inserts encoded by random 30-base pair insets. A consensus sequence for R4A
(D/E-W-D/E-Y-S/G) was identified in 36 phage clones. Of these, 23 phage clones had
identical DWEYSVWLSN amino acid sequences. A protein database search revealed that
the DWEYS consensus sequence was found in some bacterial antigens but more
surprisingly, also present in the N-terminal domains of mouse, rat, and human GluN2A and
GluN2B, but not in GluN2C and GluN2D [39].
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We have developed an in vivo model in which BALB/c mice synthesize DNRAbs following
immunization with a configuration of the DWEYS sequence multimerized on a polylysine
backbone (termed MAP-DWEYS), while BALB/c mice immunized with the polylysine
backbone alone (MAP-core) do not [40]. This model allows us to evaluate DNRAbs as
causal agents of neuronal injury, independent of other autoantibodies, and the high levels of
systemic inflammatory mediators found in spontaneous mouse SLE models. We have also
used human monoclonal DNRAbs (cloned from peripheral blood B cells of SLE patients),
which display reactivity to NMDARs, dsDNA, and DWEYS [45].

Author Manuscript

When DNRABs bind to the NMDAR, the glutamate-triggered synaptic responses become
larger, leading to greater calcium influx into the postsynaptic cell [45] (Fig. 1c). Notably,
DNRAB concentrations >100 μg per ml produce NMDAR-dependent responses of such
strength that mitochondrial cascades are activated, followed by mitochondrial permeability
transition (MPT) pore opening, and apoptosis [39, 45] (Fig. 1d, e). DNRABs can thus be
neurotoxic when they are present at sufficient levels in the brain parenchyma and interact
with neurons that are enriched with NMDARs. This particular action of DNARBs is
comparable to the neural insults that cause neurodegenerative conditions, such as those that
occur in Alzheimer and Parkinson diseases. However, it is clear that NPSLE may only
parallel a neurodegenerative disorder under severe circumstances, probably when
autoantibody is present at high titers in the brain for extended intervals (weeks).
A more likely possibility in NPSLE would be that autoantibodies enter the brain and are
extruded rather quickly (hours to days). Indeed, using a mouse model for NPSLE that carries
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high levels of circulating DNRABs (termed DNRAB+ mice), we have demonstrated that
after the autoantibodies access the brain, their levels remain elevated for 48 h but are
undetectable by 14 days [83]. Interestingly, we have shown that antibodies can only enter the
brain when DNRAB+ mice are subjected to an insult that breaches their BBB. Even more
surprising, the precise nature of the insult determines which brain region exhibits a porous
BBB. For instance, treatment with lipopolysaccharide (LPS, a bacterial toxin that produces
inflammation) induces a BBB breach around the hippocampus [40], whereas treatment with
epinephrine generates a BBB breach in the amygdala [41]. Our in vivo studies in DNRAB+
mice treated with LPS have revealed that they display a clear impairment in spatial cognition
when tested in several paradigms, such as the water maze [40], the T-maze for spatial
alternation [40, 42], the object-place-memory task [83], and the clock maze [42] (Fig. 1a).
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We have conducted in vivo studies in freely moving DNRAB+ mice that are implanted with
electrode arrays directed to the CA1 region of the hippocampus in which we record neural
signals, such as network oscillations and the activity of place cells [78, 7979, 85–87]. Our
main finding is that place cells become significantly expanded in DNRAB+ mice that have
undergone LPS treatment [83] (Fig. 1b). This irregularity becomes evident by ~2 weeks
post-LPS treatment, a time when DNRABs are no longer detectable in the hippocampus.
These results indicate that the initial DNRAB-mediated action over the NMDARs evolves
(after the triggering event is not longer present) and leads to a long-term malfunction in
spatial coding that can certainly have a deleterious effect in the spatial cognition of the
individual.
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The results in the DNRAB+ mouse model strongly suggest that subjects with SLE that are
positive for DNRABs (termed DNRAB+ patients) may exhibit noticeable problems with
spatial memory. Indeed, a novel neuropsychological task applied to these patients has
strengthened this possibility [83]. In the task, the subjects look at drawings of objects
(arranged as 2 × 2 arrays) and are later asked either an identification question not addressing
spatial relations (recognition memory) or a question about the spatial arrangement of the
array (spatial memory). DNRAB+ patients are completely normal in their recognition
memory responses but are significantly worse in their spatial memory section when
compared to healthy controls [83]. It remains to be demonstrated that the circulating
antibodies in DNRAB+ patients actually have traversed the BBB to cause hippocampal
deficit, but the data support the hypothesis that poor spatial performance in DNRAB+
patients is attributable to the presence of those antibodies.
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In conclusion, the exploration of the effects of DNRABs on NMDARs at various levels of
brain organization has generated a multilevel mechanism for their deleterious actions. The
animal studies suggest that neurotoxicity may tend to occur in DNRAB+ subjects that
exhibit high autoantibody titer and a severely compromised BBB. However, most DNRAB
actions may result in destabilization of neural networks, particularly those that underlie
spatial coding and spatial cognition if the BBB breach is limited to the hippocampus. We
propose that this integrative neuroscience approach provides an invaluable framework to
study other poorly understood NPSLE manifestations that are likely caused by brainpermeating autoantibodies.
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Analysis of the effects of DNRABs at different levels of neural organization. a The graphs
show DNRAB+ mice assessed in the clock maze, a test for spatial cognition [42]. For this
task, the apparatus is a circular base platform (diameter, 85 cm) attached to a waterproof
clear wall (30 cm high). Cold water (20 °C) is added to a depth of 2 cm. The perimeter wall
is pierced by 12 holes, 4 cm in diameter, arranged equidistantly around the circumference so
that they are 23 cm apart, like the 12 h on a clock face. The lower edge of each hole is 3 cm
above the maze floor, that is, at mouse head level. Eleven of these tubes are sealed with
black plugs, flush with the internal pool wall surface; one is open and leads to an escape
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pipe, which is 4 cm in diameter, made of black flexible plastic. Thus, from within the clock
maze, the true exit looks similar to the decoys, even to the human eye. The pool is
surrounded by distal unmoving cues, which are illuminated by focal white lights within a
darkened testing room. The task consists in escaping into the open tube and connected pipe;
the pipe is then removed and the mouse is transported to the nearby home cage. On the first
day, the mice are trained to the same exit for four trials, while on the next day a different exit
is used. Left, this group (n = 10) has circulating DNRABs that do not enter the brain and
shows normal acquisition. Right, this group (n =10) is tested 4 weeks post-LPS (which
allows DNRAB entry into the hippocampus) and shows significantly longer latency to find a
second exit (P < 0.01, ANOVA for trials 5–8), a deficit in spatial flexibility. b Left, side view
of the brain with the hippocampus highlighted in yellow. Right, neural recordings in freely
moving animals show that DNRAB+ mice exhibit larger place fields after DNRABs enter
this brain region. For these experiments, mice (n = 8) are implanted with multielectrode
arrays (4 tetrodes), directed to dorsal CA1 (coordinates of −2.0 mm AP, +1.6 mm ML from
bregma) [83–85]. Neural activity is recorded with a unitary gain headstage preamplifier
(HS-18; Neuralynx Bozeman, MT) that is connected to a programmable amplifier (Lynx-8,
Neuralynx) linked to Cheetah-32 software (Neuralynx), which acquires single units at a
sampling rate of 30 kHz (band-pass filter, 600–6 kHz). The headstage also includes two
LEDs that are used for tracking the animal’s position at 30 frames per second, which is
accomplished by linking an infrared-sensitive camera, mounted above the chamber, to the
video input of the Cheetah software. Three days post-surgery, the implanted mice are placed
in the behavioral arena over a period of 3–5 days. The figure shows representative firing rate
maps, recorded 2 weeks pre-LPS and 4 weeks post-LPS, during 10-min sessions in an arena
(viewed from the top, 40 cm on the side). Color scale indicates frequency (Hz, spikes per
second), in which red corresponds to the peak firing rate and blue to null firing. The size of
the place field is indicated below the arena. c Left, cartoon of the NMDAR showing the
binding sites for glutamate and other ligands, as well as the DWEYS consensus sequence.
Right, studies in ex vivo hippocampal slices reveal that application of DNRABs significantly
enhances the size of the extracellularly recorded NMDAR-mediated synaptic potentials. d–e
At high titer of DNRABs (>100 μg per ml), hippocampal pyramidal neurons undergo MPT
pore opening (d, detected as loss of green fluorescence in the right panel; the blue color
represents staining of cell bodies, 100 μm on the side), and apoptosis (e, detected as brown
staining by TUNEL assay, especially noticeable in the right panel inset)
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